(Q44176587)

30 November 2017

title

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study (English)

1 reference

30 November 2017

1 reference

2

Thomas C Quinn

1 reference

30 November 2017

Mark Gotfried

1

1 reference

30 November 2017

Samantha Gothelf

3

1 reference

30 November 2017

Matthew A Wikler

4

1 reference

30 November 2017

C Douglas Webb

5

1 reference

30 November 2017

Susan C Nicholson

6

1 reference

30 November 2017

language of work or name

1 reference

1 September 2002

1 reference

Diagnostic Microbiology and Infectious Disease

30 November 2017

published in

1 reference

30 November 2017

volume

44

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

85-91

1 reference

New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Clinical pharmacology of gatifloxacin, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Macrolide resistance among invasive Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Community-acquired pneumonia. Etiology, epidemiology, and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Importance of atypical pathogens of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900447-9

7 January 2021

10.1016/S0732-8893(02)00447-9

Identifiers

DOI

1 reference

30 November 2017

1 reference